As of Q4'25, Eli Lilly (LLY) reported net income of USD 6.6B, marking the highest quarterly figure in the period covered. The year-over-year (YoY) growth rate for this quarter was 50.5%, reflecting robust earnings momentum at the end of 2025. From Q1'23 to Q4'25, LLY's net income exhibited significant volatility, including a sharp dip into negative territory in Q3'23, followed by a strong recovery and sustained growth through 2024 and 2025. Notable inflection points include a dramatic YoY spike of 1,790% in Q3'24 and continued double- or triple-digit YoY growth in subsequent quarters, indicating a pronounced upward trend and accelerating profitability over the observed period.